Multimedia
Conference Coverage
Cleveland Clinic targets time to treat in cancer
CHICAGO – The Taussig Cancer Institute at the Cleveland Clinic reduced the time to treat for newly diagnosed cancer patients by 33%. Taussig’s...
Conference Coverage
Ribociclib plus endocrine therapy boosts survival of HR+/HER2- breast cancer
CHICAGO – The overall survival rate at 42 months was 70% in the combined therapy group, vs. 46% for patients treated...
Conference Coverage
In duodenal neuroendocrine tumors, resection technique matters
SAN DIEGO – Recurrence was less likely with a deeper resection technique.
Conference Coverage
Consider varying generational needs, preferences in the workplace and with patients
NASHVILLE, TENN. – Generational differences have important implications for communication, education, and more –...
Conference Coverage
Researchers propose new risk groups for NK-AML
NEWPORT BEACH, CALIF. – Investigators used machine learning algorithms to risk stratify patients with normal karyotype acute myeloid leukemia.
Conference Coverage
Combo proves most effective in HMA-naive, higher-risk MDS
NEWPORT BEACH, CALIF. – Oral rigosertib plus azacitidine produced a 90% response rate in higher-risk patients with myelodysplastic syndromes who...
Conference Coverage
More abnormal cells linked to poorer ASCT outcomes in MDS
NEWPORT BEACH, CALIF. – Patients with more than 60% cytogenetically abnormal cells at transplant had inferior overall survival and relapse-free...
Conference Coverage
Biomarker testing may transform treatment of acute GVHD
NEWPORT BEACH, CALIF. – Testing patient blood samples for two biomarkers may help guide early treatment of acute GVHD.
Conference Coverage
Model inspired by Netflix, Amazon may help guide MDS treatment
NEWPORT BEACH, CALIF. – The researchers used an algorithm to help predict response or resistance to lenalidomide with a high degree of accuracy....
Conference Coverage
Sorafenib plus GCLAM held safe in AML, MDS phase-1 study
NEWPORT BEACH, CALIF. – Sorafenib plus GCLAM has shown promise in a phase 1 trial of patients with AML and MDS.